Luke Ardolino Clinical Oncology Society of Australia Annual Scientific Meeting 2019

Abstracts this author is presenting:

• ¹⁷⁷Lu-PSMA-617 as monotherapy or in combination with NOX66 for the treatment of men with late-stage metastatic castrate resistant prostate cancer (mCRPC): An exploratory analysis. — Poster Session 1